制药提价与抑制仿制药方式 472条(本栏目收费,不能显示细节,电话13136136841)
Orange book of Hatch- Waxman, 55 55
patent infringement litigation under Paragraph IV (Hatch- Waxman Act), 22 22
pharmaceutical explanation for strong patent rights, 8 8
Abbreviated New Drug Application (ANDA),21, 118 118
See also generic drug application;Hatch- Waxman Act (U.S., 1984) AbbVie, 6 6
Abilify (antipsychotic, Otsuka), 110,12 12
acceleration clauses, 57,59 59
Accupril (hypertension drug), 53,56 56
matching petitions to relevant generic applications, 120,121 121
need for FDA transparency in, 135,136 136
overview of methodology of empirical analysis of, 115,117 117
procedural block to curb, 132,133 133
punitive deterrents to curb, 133,135 135
simple prohibition to curb, 131,132 132
staggered petitions and, 100,102 102
timing data with generic applications and, 119 119
timing of filing in relation to final approval, 123,28 28
Crestor (statin, AstraZeneca), 108,110, 111,112 112
Daraprim (antimalarial and HIV infections drug, 0
Turing Pharmaceuticals), 9,10, 84 84
Delzicol (chronic ulcerative colitis drug, Warner Chilcott), 74,76 76
Doryx (antibiotic and antimalarial drug, Warner Chilcott), 100,102 102
dosage form defined, 27 27
Drug Price Competition and Patent Term Restoration Act, 21, 32 32
See also Hatch- Waxman Act (U.S., 1984) 0
drug pricing. See pharmaceutical pricing 0